|
Protein May Stop Melanoma Before It Starts
A single protein may enable skin cells to detect genetic damage and stop growing rather than become cancerous, researchers are reporting.
The protein, IGFBP7, regulates an anticancer mechanism in normal cells that allows the cells to enter a state of arrested growth or commit suicide rather than develop into melanomas in the face of genetic damage. Understanding this process could lead to new strategies for treating the disease, the researchers say.
Dr. Michael Green of the University of Massachusetts Medical School and his colleagues reported their findings in the February 8 Cell.
Read more
Experimental Drug for Osteosarcoma Improves Overall Survival
Patients with osteosarcoma who received the experimental drug mifamurtide (L-MTP-PE) along with chemotherapy fared better than patients who received chemotherapy alone, researchers are reporting. Osteosarcoma is a rare but often fatal cancer of the bone. The disease typically affects children and young adults, and no new therapies have been introduced in two decades.
The study - conducted by the Children's Oncology Group - was the largest final-stage randomized trial in this disease and included 662 patients with newly diagnosed nonmetastatic osteosarcoma.
Read more
|
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov. |
|